NovoCure Ltd (NAS:NVCR)
$ 16.62 0.03 (0.18%) Market Cap: 1.80 Bil Enterprise Value: 1.51 Bil PE Ratio: 0 PB Ratio: 4.98 GF Score: 67/100

Q2 2020 Novocure Ltd Earnings Call Transcript

Jul 30, 2020 / 12:00PM GMT
Release Date Price: $76.17 (+12.01%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the NovoCure Second Quarter 2020 Earnings Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your host today, Ashley Cordova, Senior Vice President of Finance and Investor Relations. Please go ahead.

Ashley Cordova
NovoCure Limited - CFO & VP of IR

Good morning, everyone, and thank you for joining us to review NovoCure's second quarter 2020 performance. With the management team largely working remotely, we are again conducting today's call virtually. I am joined on the phone by our Executive Chairman, Bill Doyle; our CEO, Asaf Danziger; our CFO, Wilco Groenhuysen. Pritesh Shah, our Chief Commercial Officer; and Ely Benaim, our Chief Medical Officer, are also on the call and available for Q&A.

The slides presented today can be viewed on our website, www.novocure.com, by clicking on the link for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot